Cable One (CABO) Q1 2025 Earnings Call May 01, 2025 05:00 PM ET Company Participants Jordan Morkert - VP - Investor RelationsJulie Laulis - Chair, President & Chief Executive OfficerTodd Koetje - Chief Financial OfficerFrank Louthan - Managing Director Conference Call Participants Sebastiano Petti - Senior Research AnalystBrandon Nispel - Director & Equity Research Analyst Operator Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welc ...

Financial Data and Key Metrics Changes - Recurring and other revenue for Q3 was $421.1 million, a 15% increase year-over-year, exceeding guidance by $6.1 million [10][13] - Total revenue grew 13% compared to Q3 of the previous year, driven by strong sales execution [6][10] - Adjusted gross profit margin improved to 77%, up 110 basis points from the same quarter last year [13] - Adjusted EBITDA for Q3 was $197.1 million, representing 43.4% of revenue, significantly exceeding guidance [15][19] - Cash and cash equivalents at the end of the quarter totaled $477.8 million, with $243.8 million outstanding on the credit facility related to the Airbase acquisition [16] Business Line Data and Key Metrics Changes - The company reported strong performance in its channel referrals, with over 25% of new business coming from benefit brokers and financial advisers [10] - The integration of Airbase is progressing well, enhancing the value proposition for clients by providing a unified platform for payroll and non-payroll spending [11][56] Market Data and Key Metrics Changes - The company noted a stable client workforce level, with some seasonal hiring expected in the upcoming months [39] - There are indications of a cautious approach from some clients due to macroeconomic uncertainties, but this has not materially impacted business performance [30][99] Company Strategy and Development Direction - The company is focused on expanding its product suite, particularly in the Office of the CFO, and leveraging AI to enhance client experiences [6][9] - Continued investment in research and development is a priority, with a year-over-year increase of 14.6% in R&D spending [14] - The strategy includes a land-and-expand approach, aiming to sell additional products to existing clients while maintaining competitive pricing models [22][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's ability to drive profitability and revenue growth despite macroeconomic uncertainties [30][46] - The company anticipates continued strong performance in Q4, with increased guidance for both recurring and total revenue [19] - Management acknowledged the need to adapt sales strategies to address client concerns about cost control in uncertain economic conditions [79] Other Important Information - The company has been recognized for its workplace culture, being named one of America's greatest workplaces for women [12] - The share repurchase program remains active, with $150 million repurchased this fiscal year [16] Q&A Session Summary Question: Future pricing models and customer conversations - Management indicated that while HR buyers are accustomed to per employee pricing, new products may require different pricing models to align with CFO expectations [22] Question: Operating expenses and one-time items - Management clarified that operating expenses were consistent with expectations, with no significant one-time items affecting Q3 results [25] Question: Macro environment and hiring plans - Management noted a cautious sentiment in the market but emphasized strong execution and stability in client workforce levels [30][39] Question: Customer base dynamics and decision-making - Management observed some delays in decision-making among clients, particularly in the enterprise space, but noted overall stability in the client base [36][99] Question: Airbase integration and growth outlook - Management expressed confidence in the Airbase product's standalone performance and its potential once fully integrated [56] Question: Broker channel performance - Management highlighted the importance of the broker channel and the sustained partnerships that have contributed to new business growth [58] Question: AI innovations and customer engagement - Management reported increased customer engagement with AI features, enhancing efficiency and user experience [62][66] Question: Long-term margin expansion - Management discussed the potential for continued margin expansion, driven by operational efficiencies and revenue growth [41][72]

Reddit said advertising revenue rose 61% to $358.6 million on higher impressions and prices. Photo: dado ruvic/ReutersReddit logged higher revenue and swung to a profit in the first quarter as advertising revenue rose on higher impressions and prices.The social media company on Thursday swung to a profit of $26.2 million, or 13 cents a share, from a loss of $575.1 million, or $8.19 a share, a year earlier. ...

Financial Data and Key Metrics Changes - The company reported total revenues of $74.1 million for Q1 2025, a 61% increase compared to $46 million in Q1 2024 [19] - Net sales revenue for IBSRELA was $44.4 million, reflecting a 57% increase year-over-year [19] - Exposa generated net sales revenue of $23.4 million, up approximately 55% from $15.2 million in the same quarter last year [19][21] - The company recorded a net loss of approximately $41.1 million or $0.17 per share, compared to a net loss of $26.5 million or $0.11 per share in the prior year [23] Business Line Data and Key Metrics Changes - IBSRELA experienced strong prescription demand, with one of the highest prescription demand quarters to date [6] - Exposa grew by 30% year-over-year when excluding a one-time gross to net adjustment for return reserve release [7][21] - The gross to net deduction for IBSRELA was 34.8%, expected to improve throughout the year [20] Market Data and Key Metrics Changes - The IBS C market traditionally contracts in Q1, which was observed this year, but the company remains optimistic about recovery in subsequent quarters [31] - The dialysis market is undergoing significant disruption due to the loss of Medicare Part D coverage for phosphate-lowering therapies, impacting Exposa's market dynamics [8] Company Strategy and Development Direction - The company is focused on driving strong commercial execution for IBSRELA and navigating access complexities for Exposa [10] - The strategic imperatives include raising awareness of IBSRELA and positioning it as a first-line treatment for appropriate patients [13] - The company aims to achieve peak annual net sales revenue of over $1 billion for IBSRELA and $750 million for Exposa [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of IBSRELA and Exposa, citing strong patient demand and effective commercial strategies [5][10] - The company is closely monitoring market dynamics and will provide further updates as the landscape evolves [9] - Management remains committed to building long-term value for shareholders despite current market challenges [10] Other Important Information - The company received a $5 million milestone payment from a partner in China following the approval of a cannabinoid for hyperphosphatemia [22] - Research and development expenses increased to $14.9 million, reflecting greater engagement with scientific and medical communities [22] Q&A Session Summary Question: Expectations for the IBS C market improvement in Q2 - Management expects the IBS C market to improve as the year progresses, based on strong prescription demand observed in Q1 [31][32] Question: Details on the return reserve and its impact - The return reserve was deemed unnecessary due to zero returns and limited bottles in distribution, leading to modest improvements in gross to net going forward [29][30] Question: Insights on the Q1 contraction and its differences from previous years - The contraction is consistent with historical trends, but the company remains optimistic about future growth [35][37] Question: Long-term gross to net targets and updates on the China launch - Long-term guidance for gross to net is expected to be around 30% plus or minus 5% [40] Question: Discrepancies between reported revenue and script data for IBSRELA - Management acknowledged fluctuations in scripts and emphasized the importance of focusing on guidance rather than individual quarter performance [48][50] Question: Metrics for assessing the expanded field force's impact - Key metrics include increases in activity, new riders, and new/refill prescriptions, all of which showed positive trends in Q1 [56][57] Question: Updates on the Kidney Patient Act and potential external asset acquisitions - The Kidney Patient Act is viewed as a call option, and the company is actively pursuing external assets in renal and GI spaces [102][104]

Barfresh Food Group (BRFH) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 Good afternoon, everyone, and thank you for participating on today's first quarter twenty twenty five corporate update call for Barfresh Food Group. Joining us today is Barfresh Food Group's Founder and CEO, Ricardo Dele Coste and Barfresh Food Group's CFO, Lisa Roger. Following prepared remarks, we will open the call for your questions. The discussion today will include forward looking statements. Except for historical infor ...

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $1,036 million for Q1 2025, a 12% increase compared to $921 million in Q1 2024, with organic revenue growth of 14% [20][21] - U.S. revenue totaled $751 million for Q1 2025, up 15% from $653 million in Q1 2024 [21] - International revenue grew 7% to $286 million, with international organic revenue growth at 12% for the first quarter [24] - Gross profit was $596.2 million, representing 57.5% of revenue, down from 61.8% in Q1 2024 [26] - Operating income was $143.1 million, or 13.8% of revenue, compared to $140.2 million in the same quarter of 2024 [27] - Net income for Q1 was $127.7 million, or $0.32 per share [28] Business Line Data and Key Metrics Changes - The company experienced record new customer demand, particularly from the Type 2 non-insulin using population, indicating strong growth in this segment [10][11] - The introduction of Stello, the first over-the-counter CGM, and the CELLo biosensor has attracted a wide range of new customers [14][15] - The company is focusing on expanding its commercial reach and enhancing customer experience through software updates and broader distribution [15][16] Market Data and Key Metrics Changes - The company secured access at two of the three largest PBMs for diabetes patients, which is expected to cover nearly six million people with Type 2 diabetes by the end of the year [12][13] - International business showed strength in Japan and France, with continued growth in the DexCom One platform [25] Company Strategy and Development Direction - The company aims to build on momentum through targeted awareness campaigns and advocating for broader Type 2 coverage [12] - The introduction of new technologies and broader access is a key focus, with plans to launch the fifteen-day G7 system in the second half of the year [18][19] - The company is committed to addressing FDA recommendations following a warning letter and is working on corrective actions [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating supply dynamics and maintaining customer support during transitions [9][10] - The company is optimistic about future growth, reaffirming its revenue guidance of $4.6 billion for the year, representing 14% growth [29] - Management highlighted the importance of evidence in driving changes to standards of care and unlocking broader access globally [13] Other Important Information - The company announced a $750 million share repurchase program, reflecting confidence in its financial position [28] - Management emphasized the importance of operational efficiency and investments in technology to support growth [100][101] Q&A Session Summary Question: Did supply have any impact on the revenue growth? - Management indicated that they exited the quarter with normal supply levels, and the revenue figures reflect a normalized pattern [38] Question: Why is the full year guidance unchanged despite strong Q1 growth? - Management stated that it is early in the year, and they want to see how the rest of the year unfolds before making changes to guidance [45] Question: What are the trends in Type 2 patient utilization and reorder rates? - Management noted good retention rates in the Type 2 population, particularly with reimbursement, and strong utilization among Stellar users [53][54] Question: How exposed is the company to a potential recession? - Management believes they are well-positioned to weather economic downturns due to the cost-saving benefits of their products [62][64] Question: What is the status of the fifteen-day sensor rollout? - Management confirmed that they are working on compatibility with pump partners and securing coverage for the new product [92][93] Question: What is the path for Medicare coverage for non-insulin using Type 2 patients? - Management is actively working with CMS for approval and gathering evidence to support their case [116][119]

KeyBanc Capital Markets analyst Noah Zatzkin reiterated a Sector Weight rating on Garmin Ltd GRMN on Wednesday.Garmin reported on Wednesday first-quarter 2025 revenue growth of 11% to $1.54 billion, beating the analyst consensus estimate of $1.50 billion. The GPS navigation and wearable technology company’s adjusted EPS of $1.61 missed the consensus estimate of $1.67. Also Read: Garmin Q4 Earnings: Wearables and Adventure Watches Drive Growth, 20% Dividend Hike, Stock SoarsGarmin now expects fiscal 2025 rev ...

CVS Health Corporation (CVS) posted adjusted earnings per share (EPS) of $2.25 in the first quarter of 2025, up 71.8% year over year. The metric also topped the Zacks Consensus Estimate by 34.7%. The adjusted EPS figure considers certain asset amortization costs, loss on assets held for sale and other adjustments. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)On a reported basis, the company’s GAAP earnings were $1.41 per share compared with 88 cents in the prior-year period.CVS’ ...

PepsiCo (PEP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this food and beverage company have returned -9.1%, compared to the Zacks S&P 500 composite's -0.7% change. During this period, the Zacks Beverages - Soft drinks industry, which PepsiCo falls in, has lost 1.4%. The key question now is: What could be the stock's future direc ...

Adma Biologics (ADMA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this infectious disease drug developer have returned +17.7% over the past month versus the Zacks S&P 500 composite's -0.7% change. The Zacks Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, has lost 1.6% over this period. Now the key question is: Where could ...